Literature DB >> 17512533

Formulation of vaccines containing CpG oligonucleotides and alum.

Joan A Aebig1, Gregory E D Mullen, Gelu Dobrescu, Kelly Rausch, Lynn Lambert, Olubunmi Ajose-Popoola, Carole A Long, Allan Saul, Aaron P Miles.   

Abstract

CpG oligodeoxynucleotides are potent immunostimulants. For parenterally delivered alum-based vaccines, the immunostimulatory effect of CpG depends on the association of the CpG and antigen to the alum. We describe effects of buffer components on the binding of CPG 7909 to aluminum hydroxide (Alhydrogel), assays for measuring binding of CPG 7909 to alum and CPG 7909 induced dissociation of antigen from the alum. Free CPG 7909 is a potent inducer of IP-10 in mice. However the lack of IP-10 production from formulations containing bound CPG 7909 suggested that CPG 7909 does not rapidly dissociate from the alum after injection. It also suggests that IP-10 assays are not a good basis for potency assays for alum-based vaccines containing CPG 7909.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512533      PMCID: PMC2001166          DOI: 10.1016/j.jim.2007.04.003

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  17 in total

Review 1.  Transmission-blocking vaccines.

Authors:  David C Kaslow
Journal:  Chem Immunol       Date:  2002

2.  Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.

Authors:  Gregory E D Mullen; Birgitte K Giersing; Olubunmi Ajose-Popoola; Heather L Davis; Cheryl Kothe; Hong Zhou; Joan Aebig; Gelu Dobrescu; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2006-01-04       Impact factor: 3.641

3.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha.

Authors:  Sue E Blackwell; Arthur M Krieg
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

5.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins.

Authors:  Seema Iyer; Harm HogenEsch; Stanley L Hem
Journal:  Pharm Dev Technol       Date:  2003       Impact factor: 3.133

7.  Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Authors:  Robert Edelman; Steven S Wasserman; James G Kublin; Sacared A Bodison; Elizabeth H Nardin; Giane A Oliveira; Sobia Ansari; Carter L Diggs; Oscar L Kashala; Barbara J Schmeckpeper; Robert G Hamilton
Journal:  Vaccine       Date:  2002-12-13       Impact factor: 3.641

8.  Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

Authors:  Aaron P Miles; Yanling Zhang; Allan Saul; Anthony W Stowers
Journal:  Protein Expr Purif       Date:  2002-06       Impact factor: 1.650

9.  Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.

Authors:  Sanjay Singh; Michael C Kennedy; Carole A Long; Allan J Saul; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 10.  Use of CpG oligodeoxynucleotides as immune adjuvants.

Authors:  Dennis M Klinman; Debra Currie; Ihsan Gursel; Daniela Verthelyi
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

View more
  19 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

3.  Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses.

Authors:  Xianzhu Wu; Nagaraj M Gowda; Sanjeev Kumar; D Channe Gowda
Journal:  J Immunol       Date:  2010-03-15       Impact factor: 5.422

4.  Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

Authors:  Feng Qian; Joan A Aebig; Karine Reiter; Emma Barnafo; Yanling Zhang; Richard L Shimp; Kelly M Rausch; David S Jones; Daming Zhu; Lynn Lambert; Gregory E D Mullen; David L Narum; Louis H Miller; Yimin Wu
Journal:  Microbes Infect       Date:  2008-12-27       Impact factor: 2.700

5.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

6.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

7.  Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.

Authors:  Daming Zhu; Shuhui Huang; Holly McClellan; Weili Dai; Najam R Syed; Elizabeth Gebregeorgis; Kelly M Rausch; Gregory E D Mullen; Carole Long; Laura B Martin; David Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

8.  Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.

Authors:  Feng Qian; Karine Reiter; Yanling Zhang; Richard L Shimp; Vu Nguyen; Joan A Aebig; Kelly M Rausch; Daming Zhu; Lynn Lambert; Gregory E D Mullen; Laura B Martin; Carole A Long; Louis H Miller; David L Narum
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

9.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

10.  TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.

Authors:  Rasmus Offersen; Jesper Melchjorsen; Søren R Paludan; Lars Østergaard; Martin Tolstrup; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.